Nowadays, researchers have identified several potential biomarkers, such as, tumour infiltrating lymphocytes and programmed cell death ligand 1 (PD-L1, transcriptomic epigenetic signatures and oncogenic driver mutations.7 Among them, tumour mutation burden (TMB) is likely to be a potential biomarker. The gene discussed is CD274; the disease is neoplasm.